ITUS (NYSE:ANIX) has been assigned a $11.00 target price by investment analysts at B. Riley in a note issued to investors on Friday, TipRanks reports. The firm currently has a “buy” rating on the stock. B. Riley’s price target would indicate a potential upside of 165.70% from the company’s previous close. B. Riley also issued estimates for ITUS’s Q1 2020 earnings at ($0.25) EPS, Q2 2020 earnings at ($0.23) EPS, Q3 2020 earnings at ($0.22) EPS and Q4 2020 earnings at ($0.20) EPS.
Separately, Zacks Investment Research raised ITUS from a “hold” rating to a “buy” rating and set a $5.25 price objective for the company in a report on Tuesday, July 30th.
ITUS stock traded up $0.18 during midday trading on Friday, reaching $4.14. The stock had a trading volume of 44,841 shares, compared to its average volume of 65,362. ITUS has a 12 month low of $3.25 and a 12 month high of $6.86. The firm’s 50-day moving average price is $4.26 and its 200 day moving average price is $4.33.
ITUS Company Profile
Anixa Biosciences, Inc engages in the development, acquisition and licensing emerging technology in the field of biotechnology. It focuses on platform called Cchek, a series of inexpensive non-invasive blood tests for the early detection of cancer, which is based on the body’s immunological response to the presence of a malignancy.
Read More: What is the Russell 2000 Index?
Receive News & Ratings for ITUS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ITUS and related companies with MarketBeat.com's FREE daily email newsletter.